GoDaddy Billionaire Bob Parsons Believes Psychedelics Can Heal Trauma—And He’s Putting His Money (And Brain) On The Line
The Marine infantryman still suffers from PTSD from his tour in Vietnam but credits LSD and MDMA with helping him “come home.” Now he’s on a mission to help other veterans. On March 1, 1969, Bob Parsons was carrying a rifle through a rice paddy in the Quảng Nam province in Vietnam. As an 18-year-old […]
Numinus Completes First Extraction of its Psilocybe Mushrooms
VANCOUVER, BC, December 17, 2020 – Numinus Wellness Inc. (“Numinus” or the “Company”) (TSXV: NUMI), a company creating an ecosystem of solutions centred on the research, development, and delivery of safe, evidence-based, accessible psychedelic-assisted psychotherapies, has completed the first legal extraction of Psilocybe mushrooms in Canada by a public company for research and development purposes. This follows Numinus’ successful completion of […]
Numinus Wellness Announces National Expansion with acquisition of Mindspace Wellbeing
VANCOUVER (December 15, 2020) – Numinus Wellness Inc. (“Numinus” or “Company”) (TSXV: NUMI),a company aimed at creating an ecosystem of health solutions that develops and supports a safe, accessible and evidence-based use of psychedelic-assisted psychotherapies (PAP), is pleased to announce the acquisition of Montreal-based Mindspace Psychology Services Inc.(doing business under the name of Mindbeing, Mind wellbeing) This agreement will bring […]
MindMed Upsizes Previously Announced Bought Deal Public Offering
NEW YORK, Dec. 15, 2020 /CNW/ – Mind Medicine (MindMed) Inc. (NEO: MMED) (OTCQB: MMEDF) (DE: MMQ) (“MindMed” or the “Company”), a leading psychedelic medicine biotech company, is pleased to announce that it has agreed to increase the size of its previously announced bought deal financing led by Canaccord Genuity Corp. (the “Lead Underwriter”). The Lead Underwriter has […]
Health Canada Announces Intent to Revise Special Access Program
Health Canada announced on December 11th 2020 that it has intention to revise the Special Access Program (SAP) to allow for the safe use of MDMA (methylenedioxymethamphetamine) and psilocybin-assisted psychotherapy helping to address the huge treatment gaps that exist for a range of mental illnesses and substance use disorders. Health Canada’s notice of intent regarding […]
MindMed Announces Successful Completion of Pre-IND Meeting with the FDA for Project Lucy
NEW YORK, Dec. 14, 2020 /PRNewswire/ — MindMed (NEO: MMED,OTCQB: MMEDF, DE: MMQ), a leading psychedelic medicine biotech company today announced the successful completion of a pre-IND (Investigational New Drug) meeting with the U.S. Food and Drug Administration (FDA) regarding the development of lysergic acid diethylamide (LSD) assisted therapy for an anxiety disorder. The successful completion of this engagement with […]
MindMed Upsizes Previously Announced Bought Deal Public Offering
NEW YORK, Nov. 25, 2020 /CNW/ – Mind Medicine (MindMed) Inc. (NEO: MMED) (OTCQB: MMEDF) (“MindMed” or the “Company”), the leading neuro-pharmaceutical company for psychedelic inspired medicines, is pleased to announce that it has agreed to increase the size of its previously announced bought deal financing led by Canaccord Genuity Corp. (the “Lead Underwriter”). The Lead Underwriter […]
MindMed Announces $25 Million Bought Deal Public Offering
NEW YORK, Nov. 25, 2020 /CNW/ – Mind Medicine (MindMed) Inc. (NEO: MMED) (OTCQB: MMEDF) (“MindMed” or the “Company”), the leading neuro-pharmaceutical company for psychedelic inspired medicines, is pleased to announce that it has entered into an agreement with Canaccord Genuity Corp. (the “Lead Underwriter”) pursuant to which the Lead Underwriter has agreed, on behalf of a […]
MindMed to Launch Albert, A Digital Medicine Division for Psychedelic Medicines
NEW YORK, Nov. 24, 2020 /PRNewswire/ — MindMed (NEO: MMED) (OTCQB: MMEDF) (DE: MMQ), a leading psychedelic medicine biotech company, is establishing a digital medicine division known as Albert. Albert is in the process of assembling and recruiting a leading team of technologists, therapists, and clinical drug development experts to help the company research, develop and build an integrated technical platform and […]
Numinus Announces Compassionate Access Trial of Psilocybin-Assisted Psychotherapy for Substance Use Disorders
VANCOUVER, BC, Nov. 18, 2020 /CNW/ – Numinus Wellness Inc. (“Numinus” or the “Company”) (TSXV: NUMI), a company creating an ecosystem of solutions centred on the research, development, and delivery of safe, evidence-based, accessible psychedelic-assisted psychotherapies, has announced it will undertake a compassionate access clinical trial of psilocybin-assisted psychotherapy for substance use disorders. This study will […]
MindMed Receives Approval of Protocol Design to Evaluate Microdoses of LSD For Adult ADHD In Phase 2a Clinical Trial from Swiss and Dutch Health Authorities
NEW YORK and BASEL, Switzerland, Nov. 16, 2020 /PRNewswire/ — MindMed (NEO: MMED), (OTCQB: MMEDF), (DE: MMQ), a leading psychedelic medicine biotech company, has received a positive response on its protocol design for a Phase 2a clinical trial evaluating microdoses of LSD in the treatment of adult ADHD from the Swiss and Dutch health authorities. MindMed has also successfully submitted a […]
MindMed Announces Q3 2020 Financial Results; Cash Reserves Total $37.8 million USD ($50.1 million CAD) Post October Financing
TORONTO, Nov 13, 2020 /PRNewswire/ — MindMed (NEO: MMED) (OTCQB: MMEDF), a leading psychedelic medicine biotech company, has announced its third quarter financial results for the three and nine months ended September 30, 2020. Complete financial statements along with related management discussion and analysis can be found in the System for Electronic Document Analysis and Retrieval, the electronic filing system […]
Numinus Appoints Multidisciplinary Global Leaders to its General Advisory Council
VANCOUVER, BC, Oct. 14, 2020 /CNW/ – Recognized and respected leaders from technology, pharmacology, and health have joined Numinus Wellness Inc. (“Numinus” or the “Company”) (TSXV: NUMI) as members of the Company’s General Advisory Council. Drawing on experience across a broad range of specialities including psychedelic medicine, mental health advocacy, performance optimization, and digital healthcare, the […]
MindMed and Liechti Lab Announce R&D Collaboration On Psilocybin
BASEL, Switzerland, Sept. 24, 2020 /PRNewswire/ — Mind Medicine (MindMed) Inc. (NEO: MMED)(OTC: MMEDF), the leading drug development company for psychedelic inspired medicines, announces that the company has been conducting R&D work on psilocybin in collaboration with the University Hospital Basel’s Liechti Lab in a study to better understand and compare the altered states of […]
Numinus Commences Psilocybe Mushroom Cultivation at its Health Canada Licensed Laboratory
VANCOUVER, BC, Sept. 24, 2020 /CNW/ – Numinus Wellness Inc. (“Numinus” or the “Company”) (TSXV: NUMI), a company creating an ecosystem of health solutions centred on developing and supporting the safe, evidence-based, accessible use of psychedelic-assisted psychotherapies, is pleased to announce it has begun cultivating Psilocybe mushrooms, for the purpose of psilocybin production, at its 7000 square-foot Health […]
MindMed Submits Application For NASDAQ Up-Listing, Appoints Canaccord Genuity As Financial Advisor
NEW YORK, Sept. 21, 2020 /PRNewswire/ — Mind Medicine (MindMed) Inc. (NEO: MMED)(OTCQB: MMEDF)(DE: MMQ), the leading drug development company for psychedelic inspired medicines, is evaluating an expanded United States investor base through an up-listing on the NASDAQ Capital Market (“NASDAQ”). As part of this up-listing strategy in the United States, MindMed has submitted an application […]
Numinus Announces Closing of Oversubscribed $4.6 Million Offering
Vancouver, British Columbia, September 10, 2020, Numinus Wellness Inc. (“Numinus” or the “Company”) (TSXV: NUMI), is pleased to announce that it has closed its previously announced short form prospectus offering, on a best efforts basis, including the exercise of the agent’s option in its entirety in the form of units of the Company (each, a […]
Numinus Announces Filing of Final Short Form Prospectus for Offering of up to $4,000,000
Numinus Wellness Inc. (“Numinus” or the “Company“) (TSXV: NUMI), a company creating an ecosystem of health solutions centred on developing and supporting the safe, evidence-based, accessible use of psychedelic-assisted therapies, is pleased to announce it has filed a final short form prospectus (the “Prospectus“) dated September 1, 2020 in connection with its previously announced best-efforts offering. […]
Numinus Announces Listing of Warrants
VANCOUVER, BC, Sept. 18, 2020 /CNW/ – Numinus Wellness Inc. (“Numinus” or the “Company“) (TSXV: NUMI), a company creating an ecosystem of health solutions centred around developing and supporting the safe, evidence-based, accessible use of psychedelic-assisted psychotherapy, is pleased to announce that the TSX Venture Exchange (“TSXV“) has accepted for listing the 9,200,000 warrants (the “Warrants“) […]
Phase 2 Clinical Trial of LSD for “Suicide Headaches” Begins Treating Patients
MindMed Is Collaborating on a Phase 2 Clinical Trial of LSD For Cluster Headaches with University Hospital Basel’s Liechti Lab Basel, Switzerland, June 8, 2020 /PRNewswire/ — Mind Medicine (MindMed) Inc. (NEO: MMED OTCQB:MMEDF), is supporting and collaborating on a Phase 2 clinical trial evaluating LSD for the treatment of cluster headaches at University Hospital […]
Champignon Identifies Synthetic Ketamine and Psilocybin Metabolite Targets
VANCOUVER, British Columbia, June 8, 2020 – Champignon Brands Inc. (“Champignon” or the “Company”) (CSE: SHRM) (FWB: 496) (OTCQB: SHRMF), a human optimization sciences company with an emphasis on ketamine and psychedelic medicine, is pleased to announce it has selected Toronto-based Dalriada Drug Discovery Inc. (“Dalriada”) to advance its new chemical entity (“NCE”) IP portfolio […]
MindMed’s Microdosing Division Further Expands Phase 2 Clinical Trial of Microdosing LSD For Adult ADHD
Adds Clinical Trial Site at University Hospital Basel and Appoints World Leading Psychedelics ResearcherDr. Matthias Liechti as Principal Investigator BASEL, Switzerland, June 2, 2020 /PRNewswire/ — Mind Medicine(MindMed) Inc. (NEO: MMED OTCQB: MMEDF) is expanding its Phase 2a clinical trial of LSD microdosing for Adult ADHD. MindMed is the leading neuro-pharmaceutical company for psychedelic […]
CHAMPIGNON Announces Voluntary SHARE LOCK-UP; Retains GOLD STANDARD MEDIA, LLC for Financial Marketing Services
ANCOUVER, British Columbia, May 29, 2020 – Champignon Brands Inc. (“Champignon” or the “Company”) (CSE: SHRM) (FWB: 496) (OTCQB: SHRMF), a human optimization sciences company with an emphasis on ketamine and psychedelic medicine, today announces that certain shareholders have agreed to a voluntary resale restriction period covering 17,840,000 common shares extending the period of time before the […]
MindMed Adds MDMA to Develop Next-Gen Psychedelic Therapies
MindMed Further Expands R&D Collaboration with University Hospital Basel’s Liechti Lab with Plans To Develop Next-Gen Psychedelic Therapies Combining LSD and MDMA NEW YORK, May 27, 2020 /PRNewswire/ — Mind Medicine (MindMed) Inc. (NEO: MMEDOTCQB: MMEDF), the leading neuro-pharmaceutical company for psychedelic inspired medicines, is now adding the psychedelic compound MDMA to its R&D pipeline. The […]
Numinus Wellness Inc. Commences Trading TSX.V:NUMI
VANCOUVER, May 20, 2020 /CNW/ – With momentum building for the use of psychedelic assisted therapies in addressing the growing problems of mental illness, addiction and trauma, Vancouver-based Numinus Wellness Inc. began trading today on the TSX Venture Exchange under the symbol NUMI as one of the first in-market, fully integrated companies in the psychedelic […]
Champignon Sponsors TheraPsil
VANCOUVER, British Columbia, May 18, 2020 – Champignon Brands Inc. (“Champignon” or the “Company”) (CSE: SHRM) (FWB: 496) (OTCQB: SHRMF), a human optimization sciences Company with an emphasis on ketamine and psychedelic medicine, is pleased to sponsor TheraPsil, a BC-based non-profit coalition of healthcare professionals, policy-makers and community leaders (the “TheraPsil Coalition”) seeking legal access […]
MindMed reports First Quarter 2020 Results
TORONTO, May 14, 2020: Mind Medicine (MindMed) Inc. (“MindMed” or the “Company”) (NEO: MMED, OTCQB: MMEDF), the leading neuro-pharmaceutical company for psychedelic inspired medicines, today announced the release of its unaudited condensed consolidated financial statements (the “Financial Statements”) and accompanying management’s discussion and analysis (the “MD&A”) for the quarter ended March 31, 2020. All financial […]
Champignon Expands to the USA – Aquires Ketamine Centre
VANCOUVER, British Columbia, May 12, 2020 – Champignon Brands Inc. (“Champignon” or the “Company”) (CSE: SHRM) (FWB: 496) (OTCQB: SHRMF), a human optimization sciences Company with an emphasis on ketamine and psychedelic medicine is pleased to announce that it has executed a term sheet (the “Term Sheet”) with California, U.S. based Wellness Clinic of Orange […]
Champignon $10,000,000 Placement
VANCOUVER, British Columbia, May 11, 2020 – Champignon Brands Inc. (“Champignon” or the “Company”) (CSE: SHRM) (FWB: 496), is pleased to announce that it has entered into an agreement with Canaccord Genuity Corp. (“Canaccord Genuity”) and Eight Capital (“Eight” and together with Canaccord Genuity, the “Co-Lead Underwriters”), to purchase, on a bought deal private placement […]
Champignon Appoints Dr. McIntryre as CEO
VANCOUVER, British Columbia, May 11, 2020 – Champignon Brands Inc. (“Champignon” or the “Company”) (CSE: SHRM) (FWB: 496) (OTCQB: SHRMF), a human optimization sciences Company with an emphasis on ketamine and psychedelic medicine, is pleased to announce that it has appointed Dr. Roger McIntyre as Chief Executive Officer. Dr. McIntyre is a Professor of Psychiatry […]
MindMed Advances Phase 2 LSD Microdosing Trial
TORONTO – May 11, 2020 – Mind Medicine (MindMed) Inc. (NEO: MMED; OTC: MMEDF) ( (“MindMed” or the “Company”) is pleased to announce that, on May 8, 2020, it has entered into a clinical trial agreement with Maastricht University to undertake a Phase 2a clinical trial for lysergic acid diethylamide (“LSD”) in adult patients with […]
Champignon appoints to Special Advisory Board
VANCOUVER, British Columbia, March 25, 2020 – Champignon Brands Inc. (“Champignon” or the “Company”) (CSE: SHRM) (FWB: 496) (OTC: SHRMF), a health and wellness company specializing in the formulation of a suite of medicinal mushroom health products, as well as novel delivery platforms for the pharmaceutical and nutraceutical industries, continues to bolster its Special Advisory […]
Champignon forms North American Clinical Expansion Committee
VANCOUVER, British Columbia, May 4, 2020 – Champignon Brands Inc. (“Champignon” or the “Company”) (CSE: SHRM) (FWB: 496) (OTCQB: SHRMF), a human optimization sciences company focused on applying novel and natural treatment protocols to address a broad range of disorders and deficiencies with an emphasis on psychedelic medicine, has advanced its North American new clinical […]
Champignon Ketamine Treatment to be Dispensed by Major Canadian Chain
VANCOUVER, British Columbia, April 30, 2020 – Champignon Brands Inc. (“Champignon” or the “Company”) (CSE: SHRM) (FWB: 496) (OTCQB: SHRMF), a human optimization sciences company focused on applying novel and natural treatment protocols to address a broad range of disorders and deficiencies with an emphasis on psychedelic medicine, continues to strengthen its vertically integrated psychedelic […]
Champignon Selected as Headline Partner
VANCOUVER, British Columbia, April 28, 2020 – Champignon Brands Inc. (“Champignon” or the “Company”) (CSE: SHRM) (FWB: 496) (OTCQB: SHRMF), a human optimization sciences company focused on applying novel and natural treatment protocols to address a broad range of disorders and deficiencies with an emphasis on psychedelic medicine, is pleased to announce it has been […]
Champignon Trading on OTCQB
VANCOUVER, British Columbia, April 23, 2020 – Champignon Brands Inc. (“Champignon” or the “Company”) (CSE: SHRM) (FWB: 496) (OTCQB: SHRMF), a human optimization sciences company focused on applying novel and natural treatment protocols to address a broad range of disorders and deficiencies with an emphasis on psychedelic medicine, is pleased to announce that its common […]
Champignon Secures Psilocybin Supply for Research
VANCOUVER, British Columbia, April 22, 2020 – Champignon Brands Inc. (“Champignon” or the “Company”) (CSE: SHRM) (FWB: 496) (OTC: SHRMF), a human optimization sciences company focused on applying novel and natural treatment protocols to address a broad range of disorders and deficiencies with an emphasis on psychedelic medicine, continues to advance its clinical pipeline via […]
Champigon Receives DTC Eligibilty
VANCOUVER, British Columbia, April 17, 2020 – Champignon Brands Inc. (“Champignon” or the “Company”) (CSE: SHRM) (FWB: 496) (OTC: SHRMF), a human optimization sciences company focused on applying novel and natural treatment protocols to address a broad range of disorders and deficiencies with an emphasis on psychedelic medicine, is pleased to announce its common shares […]
Champignon Appoints Special Advisor
VANCOUVER, British Columbia, April 16, 2020 – Champignon Brands Inc. (“Champignon” or the “Company”) (CSE: SHRM) (FWB: 496) (OTC: SHRMF), a human optimization sciences company focused on applying novel and natural treatment protocols to address a broad range of disorders and deficiencies with an emphasis on psychedelic medicine, has further bolstered its pharmaceutical, nutraceutical and […]
Champignon Acquires Altmed Capital Corp.
ANCOUVER, British Columbia, April 9, 2020 – Champignon Brands Inc. (“Champignon” or the “Company”) (CSE: SHRM) (FWB: 496) (OTC: SHRMF), a human optimization sciences company focused on applying novel and natural treatment protocols to address a broad range of disorders and deficiencies with an emphasis on psychedelic medicine, continues to accelerate its advancements within the […]
Champignon Appoints Special Advisor
VANCOUVER, British Columbia, March 31, 2020 – Champignon Brands Inc. (“Champignon” or the “Company”) (CSE: SHRM) (FWB: 496) (OTC: SHRMF), a human optimization sciences company focused on applying novel and natural treatment protocols to address a broad range of disorders and deficiencies with an emphasis on psychedelic medicine, continues to augment its Special Advisory Committee […]
Champignon Expands Preclinical Pipeline
VANCOUVER, British Columbia, March 27, 2020 – Champignon Brands Inc. (“Champignon” or the “Company”) (CSE: SHRM) (FWB: 496) (OTC: SHRMF), a health and wellness company specializing in the formulation of medicinal mushrooms health products and novel delivery platforms for the pharmaceutical and nutraceutical industries, has entered into a definitive agreement to acquire Tassili Life Sciences […]
MindMed NEO:MMED
Mindmed is developing therapeutic treatments from psychedelic substances to improve health and wellness. Assembling the most compelling IP portfolio of psychedelic inspired medicines for FDA clinical trials & commercialization. The legalization of psychedelic inspired medicines will be different than cannabis. FDA will regulate as drug therapies using clinical trials.
Champignon Brands CSE:SHRM
Champignon Brands Inc. is a Canadian based company dedicated to the cultivation, distribution and proliferation of artensial, medicinal mushrooms and associated CPGs. The Champignon team believes that we can enhance the health and wellness of millions of consumers through organic growing practices, commercial cultivation, R&D and the distribution of our premium, mushroom-infused suite of products.